Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis
- 1 May 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Neuropharmacology
- Vol. 32 (3), 121-132
- https://doi.org/10.1097/wnf.0b013e3181880359
Abstract
Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system of uncertain etiology. There is consensus that a dysregulated immune system plays a critical role in the pathogenesis of MS; therefore, we aim to summarize current hypotheses concerning the complex cellular and molecular interactions involved in the immunopathology of MS. Although CD4+ T lymphocytes have long been implicated in the immunopathology of MS, the role of other T-cell subtypes has been recognized. CD4+ and CD8+ cells have been isolated from different locations within MS lesions and gamma/delta T cells have been isolated from early MS lesions. The prevalent dogma has been that CD4+ TH1 cells release cytokines and mediators of inflammation that may cause tissue damage, although CD4+ TH2 cells may be involved in modulation of these effects. Recent evidence, however, suggests that additional T-cell subsets play a prominent role in MS immunopathology: TH17 cells, CD8+ effector T cells, and CD4+CD25+ regulatory T cells. In addition, laboratory and clinical data are accumulating on the prominent role of B lymphocytes and antigen-presenting cells in MS pathogenesis. On the basis of these observations, new therapeutic approaches for MS will need to focus on resetting multiple components of the immune system.Keywords
This publication has 101 references indexed in Scilit:
- Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosisJournal of Neuroimmunology, 2007
- Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selectionJournal of Neuroimmunology, 2007
- Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured proteinNature Medicine, 2007
- Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patientsClinical and Experimental Immunology, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Interleukin-10 determines viral clearance or persistence in vivoNature Medicine, 2006
- Interferon after 10 years in patients with multiple sclerosisNeurological Sciences, 2006
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2006
- Natalizumab and PMLNature Neuroscience, 2005
- In Vitro Cell-Mediated Immunity of Cerebrospinal-Fluid Lymphocytes to Myelin Basic Protein in Primary Demyelinating DiseasesNew England Journal of Medicine, 1977